What Medicare’s DMHT Codes Signal for Digital Therapeutics Reimbursement and Why Healthcare Is Paying Attention
Digital therapeutics reimbursement refers to how public and private healthcare systems pay for evidence-based software that delivers clinically supervised treatment. Digital therapeutics are not apps that later become reimbursed.
They are regulated medical treatments that may later become paid.
Medicare’s new Digital Mental Health Treatment (DMHT) codes do not legitimise wellness software. They reward prescription-grade, FDA-authorised software that delivers treatment under clinical supervision.
In short:
• Digital therapeutics are now reimbursed in the U.S. but narrowly
• Medicare’s DMHT codes reward supervised treatment, not engagement
• Early adoption is about correctness, not scale
• What Medicare does next will shape global digital therapeutics reimbursement
Digital therapeutics reimbursement under Medicare’s DMHT framework does not involve a centralised application, manufacturer dossier, or payer submission process. Unlike health technology assessments or national coverage decisions in other systems, reimbursement access occurs operationally through clinicians who prescribe, supervise, and bill for care using existing Medicare codes.
For digital therapeutics teams accustomed to HTA-style submissions, this represents a structural shift: reimbursement readiness is demonstrated through regulatory status, clinical workflows, documentation, and outcomes not through a standalone reimbursement application.
If a product is not regulated as a medical device by the U.S. Food and Drug Administration, it remains invisible to these pathways regardless of engagement, AI sophistication, or user growth.
Digital therapeutics reimbursement in 2026 is not awarded through a standalone application or approval process.
Instead, reimbursement eligibility is determined by how a digital therapeutic is regulated, prescribed, supervised, and documented within existing healthcare payment frameworks.
Under Medicare’s Digital Mental Health Treatment (DMHT) codes, reimbursement depends on whether the software is classified as a regulated medical device, delivers evidence-based treatment rather than monitoring, remains under licensed clinical supervision, and is used within a recognised billing structure.
In practice, reimbursement is earned through correct clinical use, documented oversight, and alignment with payer accountability requirements — not through engagement metrics or product claims.
How Digital Therapeutics Are Awarded Reimbursement in 2026
Digital therapeutics reimbursement in 2026 is not awarded through an application process. It is accessed operationally through clinicians and healthcare systems when four conditions are met:
• the digital therapeutic is regulated as a medical device
• the software delivers evidence-based treatment, not monitoring
• a licensed clinician remains accountable for care
• the intervention fits an existing reimbursement framework, such as Medicare’s Digital Mental Health Treatment (DMHT) codes
In practice, reimbursement is earned through correct clinical use, documented supervision, and alignment with payer logic not through product claims or engagement metrics.
For most of the past decade, digital therapeutics existed in a reimbursement gap: clinically ambitious, increasingly regulated, yet rarely paid for through formal healthcare reimbursement systems.
Companies like Click Therapeutics, Akili, and Pear Therapeutics demonstrated early that software could change patient outcomes. What they could not demonstrate, at least not consistently, was how healthcare systems should pay for software that behaved like medicine but looked, to finance departments, like an app.
The problem was never innovation.
It was a translation. For a decade, digital therapeutics were clinically promising but financially homeless.”
“Reimbursement, not innovation, was the missing infrastructure.
That is now beginning to change. Digital therapeutics succeed or fail not on engagement curves, but on whether reimbursement systems recognise them as treatment. Reimbursement is how healthcare systems express belief. Until now, digital therapeutics had not earned it.
What Medicare’s DMHT Codes Actually Do
In 2025, Centers for Medicare & Medicaid Services quietly introduced a new reimbursement pathway under Medicare: Digital Mental Health Treatment (DMHT) codes. For the first time, U.S. clinicians can be paid for software-delivered treatment not monitoring, not adherence nudges, but regulated, clinician-supervised digital therapy.
While this article focuses on U.S. digital therapeutics reimbursement, Medicare policy often acts as a reference point for how digital therapeutics are reimbursed globally.
When Medicare establishes new reimbursement pathways for digital therapeutics, private insurers, employer health plans, and international health systems closely observe how those therapeutics are classified, supervised, and paid for.
Medicare has a long history of acting as a global signalling mechanism. When it creates a new benefit category, other systems’ private insurers, employer plans, and international payers take notice. The same pattern played out with telehealth, remote monitoring, and chronic care management. What begins as cautious, scoped reimbursement often becomes a reference point far beyond American borders.
The DMHT codes are not the end state for digital therapeutics. They are a proof-of-structure moment: evidence that healthcare systems are learning how to classify, supervise, and pay for software as treatment.
What comes next Prescription Digital Therapeutics (PDTx), algorithm-based services, and AI-enabled care pathways will determine whether digital therapeutics finally cross the threshold from interesting innovation to durable healthcare infrastructure.
This article explains what that shift really means:
- why Medicare moved first, and why it moved carefully
- which companies are positioned to benefit and which are not
- how reimbursement logic is evolving from mental health into broader disease areas
- and what digital therapeutics teams must do now to avoid repeating the mistakes of the past decade
Digital therapeutics reimbursement became operational in the U.S. in 2025 through Medicare’s Digital Mental Health Treatment (DMHT) codes.
Reimbursement for digital therapeutics now depends on clinical supervision, regulatory status, and outcomes, not engagement alone.
Early Medicare reimbursement for digital therapeutics is a policy signal, not a scale test.
Many founders assume few digital therapeutics are being approved because there are few announcements.
In reality, the opposite is true.
The FDA regulates digital therapeutics as medical devices, not drugs. They are authorised through 510(k) or De Novo pathways, not headline-grabbing approvals.
This silence is not neglect. It is maturity.
Software-based treatments are now routine enough to be reviewed without spectacle — which is precisely what allows reimbursement systems to follow.
DMHT reimbursement is a transitional step toward broader Prescription Digital Therapeutics (PDTx) reimbursement.
Digital therapeutics companies that align evidence, workflow, and reimbursement strategy early will scale first.
Illustrative Digital Therapeutics Companies and Reimbursement Readiness (2025) The table below illustrates how different digital therapeutics companies have interacted with reimbursement systems — and why outcomes have varied.
| Company | Digital Therapeutic Focus | Regulatory Status | Primary Reimbursement Exposure | Key Reimbursement Lesson |
|---|---|---|---|---|
| Click Therapeutics | Mental health, migraine, schizophrenia | FDA-authorised SaMD | Medicare (DMHT), commercial payers | Demonstrates that drug-like endpoints + clinician supervision enable reimbursable digital therapeutics |
| Akili | Paediatric ADHD | FDA De Novo | Commercial plans, employers | Shows limits of reimbursement when digital therapeutics lack clear Medicare pathways |
| Pear Therapeutics (defunct) | Substance use disorder | FDA-authorised | Attempted payer coverage | Illustrates that regulatory approval alone does not guarantee sustainable reimbursement |
| Omada Health | Diabetes, cardiometabolic care | FDA-cleared components | Employer & population health budgets | Highlights alternative reimbursement routes outside Medicare for digital therapeutics |
| Kaia Health | Musculoskeletal pain | CE-marked SaMD | Selective payer contracts | Shows condition-specific reimbursement strategies for digital therapeutics |
| Voluntis | Oncology, chronic disease | FDA + CE-marked | Pharma-linked reimbursement | Demonstrates how digital therapeutics integrate into drug reimbursement pathways |
| Propeller Health | Respiratory disease | FDA-cleared device + software | Payer and life-sciences partnerships | Illustrates hybrid device-software reimbursement logic relevant to Medicaid and Medicare |
Why There Is No Single “DMHT Code” and How Digital Therapeutics Enter Reimbursement
Medicare’s Digital Mental Health Treatment (DMHT) framework does not rely on a single, standalone billing code assigned to a product. This is deliberate. Rather than approving or reimbursing individual digital therapeutics, the Centers for Medicare & Medicaid Services has defined reimbursable clinical activities: clinician-supervised, software-delivered mental health treatment that can be documented, audited, and managed within existing professional service billing structures. In this model, reimbursement is tied to what the clinician does, prescribing, supervising, reviewing progress, and adjusting care—not to the digital therapeutic itself. Digital therapeutics become reimbursable by functioning as treatment modalities within these defined activities, aligning their intended use, evidence, and workflows to clinician-delivered care rather than attempting to secure a product-specific reimbursement designation. This reflects a broader CMS principle: healthcare systems reimburse accountable care delivery, not technology in isolation.
Why Digital Therapeutics Reimbursement Finally Became Possible
For years, the problem with digital therapeutics was not science. It was a digital reimbursement.
Healthcare systems struggled to answer a deceptively simple question:
How do you pay for software that delivers treatment but doesn’t fit existing billing categories?
Most reimbursement frameworks were built for two things people and products. Clinicians bill for time. Drugs and devices bill for units. Digital therapeutics sit awkwardly in between: they deliver ongoing therapy, adapt over time, and generate value through interaction rather than consumption.
The result was a decade of workaround solutions. Digital therapeutics were squeezed into:
- wellness budgets
- pilot grants
- employer contracts
- innovation funds
- or temporary coverage exceptions
None of these created durable reimbursement. And without durable reimbursement, even clinically strong digital therapeutics struggled to scale.
That is why the 2025 Medicare Digital Mental Health Treatment (DMHT) codes matter. They represent the first time a major payer has explicitly redesigned digital reimbursement logic around how digital therapeutics actually work.
Instead of asking software to behave like a pill, CMS did something more pragmatic:
it asked clinicians to remain accountable for care, and allowed software-delivered treatment to be reimbursed through supervised clinical management.
This may sound incremental. It is not.
It marks a shift away from treating digital therapeutics as tools that support care and toward recognising them as modalities that deliver care with reimbursement structured accordingly.
From a digital reimbursement perspective, this is a crucial distinction. It means:
- Payment is tied to therapeutic intent, not device ownership
- Clinical oversight is rewarded, not bypassed
- Outcomes and documentation matter more than downloads or engagement curves
In other words, digital therapeutics are being evaluated using the same logic applied to other reimbursed treatments:
Is there evidence? Is there accountability? Is there a way to audit value?
This is why digital reimbursement is now advancing condition by condition, rather than through a single sweeping benefit category. Mental health came first because:
- outcomes are measurable
- clinician supervision is well defined
- unmet need is visible
- and cost offsets are easier to demonstrate
But the implications extend far beyond behavioural health. Once healthcare systems learn how to reimburse digital therapeutics safely in one domain, the same logic becomes transferable to others chronic disease, pain, sleep, cardiometabolic care, and beyond.
Digital reimbursement does not arrive as a blank cheque.
It arrives as a new set of rules.
The companies that succeed will not be those with the most users or the loudest narratives, but those that understand how reimbursement systems think and design their digital therapeutics accordingly.
Early Adoption: How to Read the DMHT Reimbursement Signal
Early utilisation of Medicare’s Digital Mental Health Treatment (DMHT) codes has been modest. That has led some observers to ask whether digital therapeutics reimbursement is really taking hold.
That question misunderstands how Medicare introduces new payment models.
When Centers for Medicare & Medicaid Services creates a new reimbursement pathway, early volume is not the goal. Behaviour is.
In the first year of a new code, CMS is primarily assessing:
- whether clinicians understand when the code applies
- whether documentation standards are being met
- whether billing patterns align with clinical intent
- and whether patient selection appears appropriate
Low early volume is not a warning sign. It is a safeguard.
CMS has used this approach repeatedly with chronic care management, transitional care management, telehealth, and remote monitoring. In each case, reimbursement expanded only after CMS was confident that providers were using the codes as designed, not opportunistically.
The same logic applies to digital therapeutics reimbursement.
Early DMHT claims are doing several important things at once:
- proving that clinicians will prescribe regulated digital therapeutics
- showing that software can be integrated into supervised treatment plans
- generating real-world documentation and audit data
- establishing baseline outcomes and utilisation patterns
From a policy perspective, this phase is about learning how digital therapeutics behave inside the reimbursement system.
For companies, the lesson is practical and often missed:
Early reimbursement is not about scale, it is about correctness.
The digital therapeutics teams that benefit most from this phase are not those chasing volume, but those using early adoption to:
- refine clinical workflows
- stress-test documentation and revenue-cycle processes
- validate outcome measures under real payer scrutiny
- and build credibility with prescribing clinicians
CMS does not expand reimbursement categories based on enthusiasm.
It expands them based on evidence that a payment model can be controlled, audited, and justified.
That is why early DMHT utilisation should be read as a signal that digital reimbursement is functioning — cautiously, deliberately, and exactly as intended.
For digital therapeutics developers, this phase offers a narrow but valuable window: an opportunity to align products, evidence, and workflows with how reimbursement systems actually operate, before broader expansion makes mistakes harder to correct.
What Digital Therapeutics Reimbursement Covers and What It Deliberately Does Not
One reason digital therapeutics reimbursement has advanced cautiously is that CMS has been explicit about boundaries.
The Digital Mental Health Treatment (DMHT) codes do not reimburse “digital health” broadly. They reimburse a very specific clinical construct: regulated digital therapeutics used within a clinician-supervised behavioural health treatment plan.
This distinction is intentional.
Under Medicare’s DMHT framework, reimbursement applies only when:
- the digital therapeutic is classified as a regulated medical device
- the intervention delivers evidence-based mental health treatment
- a licensed clinician remains accountable for care decisions
- therapeutic use and clinical time are documented
What is excluded is equally important.
DMHT does not reimburse:
- general wellness or self-help apps
- unregulated mental health platforms
- passive symptom trackers or content libraries
- standalone consumer subscriptions without clinical oversight
From a digital reimbursement perspective, this clarity matters. It reduces the risk that new payment pathways are diluted by low-value or poorly defined interventions a problem that has undermined earlier digital health initiatives.
It also signals how CMS is thinking about future expansion.
Rather than creating a broad, permissive digital benefit, Medicare is testing whether software-based treatment can be controlled, supervised, and audited in the same way as other reimbursed clinical services.
Mental health was selected first not because it is the only suitable domain, but because:
- outcomes are measurable
- supervision models already exist
- treatment plans are well defined
- and unmet need is visible to payers
The implication for digital therapeutics beyond mental health is straightforward:
future reimbursement will follow the same logic, not the same labels.
Products in other disease areas will not be reimbursed because they are “digital.” They will be reimbursed if they can demonstrate:
- therapeutic intent
- clinical accountability
- measurable outcomes
- and economic relevance
This is how reimbursement systems learn by narrowing scope before expanding it.
Understanding what DMHT does not cover is therefore as important as understanding what it does. It reveals the reimbursement rules that digital therapeutics will be expected to meet as coverage moves toward broader Prescription Digital Therapeutics (PDTx) frameworks.
Where This Is Headed and How Sensible Systems Will Decide What Gets Paid
If digital therapeutics reimbursement feels cautious, that is because it is meant to be.
From a policy perspective, the Digital Mental Health Treatment (DMHT) codes are not a declaration of victory for digital therapeutics. They are a controlled experiment. Medicare is testing whether software-based treatments can be supervised, documented, audited, and paid for without undermining the integrity of the reimbursement system.
From a health-economics perspective, this caution is rational.
Reimbursement systems are designed to manage three risks at once:
- clinical risk (does the intervention work?)
- financial risk (will spending escalate uncontrollably?)
- behavioural risk (will providers use it as intended?)
Digital therapeutics challenge all three, not because they are unsafe, but because they do not behave like traditional billable items. They are iterative, adaptive, and ongoing. That makes them powerful and hard to price.
What Medicare is doing with DMHT is narrowing the problem.
By anchoring reimbursement to clinician time, supervised treatment plans, and regulated software, Centers for Medicare & Medicaid Services has created a framework that answers the core economic question: who is accountable for outcomes when software delivers treatment?
That answer matters more than the technology itself.
If accountability sits with clinicians, and outcomes can be measured, reimbursement becomes possible. If accountability is diffuse, or outcomes are unclear, payment stalls regardless of how innovative the software appears.
This logic explains why mental health came first. It also explains what will come next.
As policymakers evaluate early DMHT data, they will be asking practical questions:
- Are clinicians using the codes appropriately?
- Do outcomes justify the spend?
- Are there identifiable cost offsets or value signals?
- Can utilisation be forecast and controlled?
If the answers are yes, expansion follows not as a leap, but as an extension. As of 2025, digital therapeutics reimbursement in the United States is no longer theoretical; it is governed by Medicare policy, defined reimbursement codes, and enforceable clinical requirements.
This is where Prescription Digital Therapeutics (PDTx) enters the picture. A statutory benefit category would not be a reward for digital innovation. It would be an acknowledgement that software-delivered treatment can now be governed by the same economic rules as other medical interventions.
From an economic standpoint, that is the threshold that matters.
Digital therapeutics will not be reimbursed because they are cheaper, more scalable, or technologically impressive. They will be reimbursed because they:
- substitute for, or complement, existing reimbursed care
- produce measurable clinical outcomes
- operate within accountable delivery models
- and fit within budgetary constraints
The companies that succeed will be those that understand this early.
They will design products not just for patients, but for payment systems aligning evidence generation, clinical workflows, and economic narratives long before reimbursement decisions are made.
The mistake of the last decade was assuming that proof of clinical benefit alone would unlock payment. The lesson of 2025 is more grounded: reimbursement follows structure, not enthusiasm.
Digital therapeutics are now being tested against that structure. Some will pass. Many will not.
The question facing the field is no longer whether software can deliver care.
It is whether companies are willing to build digital therapeutics that reimbursement systems can recognise, control, and sustain.
That is where this story ends and where the real work begins.
Policy Sources Informing Digital Therapeutics Reimbursement (2024–2025)
U.S. Medicare Physician Fee Schedule (2025) — Introduced Digital Mental Health Treatment (DMHT) reimbursement codes, formally recognising clinician-supervised digital therapeutics as reimbursable treatment under Medicare. https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2025-medicare-physician-fee-schedule-final-rule
Centers for Medicare & Medicaid Services (CMS): Behavioural Health Integration Guidance — Clarifies supervision, documentation, and accountability requirements relevant to reimbursable digital mental health treatment. https://www.chcs.org/media/ACO-LC-BH-Integration-Paper-070914.pdf
Access to Prescription Digital Therapeutics Act (S.1702 / H.R.3288) U.S. congressional proposal to establish a statutory benefit category for Prescription Digital Therapeutics (PDTx), extending digital therapeutics reimbursement beyond mental health.
Health Tech Investment Act (S.1399) Legislative proposal addressing reimbursement for algorithm-based and AI-enabled healthcare services, including software-driven clinical interventions.
Medical Coding and Reimbursement Guidance (2025) Industry interpretation of DMHT billing workflows, time-based coding requirements, and compliance considerations.
Peer-Reviewed Research on Digital Therapeutics Evidence Standards — Analyses of clinical trial design, outcome measurement, and payer-relevant evidence for regulated digital therapeutics.
International Digital Therapeutics Reimbursement Experience Lessons from structured digital therapeutics reimbursement programmes in Europe, informing phased adoption and payer risk management.
Frequently Asked Questions: Digital Therapeutics Reimbursement (2025)
Who can currently apply for digital therapeutics reimbursement in the U.S.?
Reimbursement is not applied for by the digital therapeutics company directly. It is accessed through clinicians and healthcare providers who prescribe and manage regulated digital therapeutics as part of patient care.
Under current Medicare policy, eligible providers include licensed behavioural health clinicians operating within supervised treatment plans.
Which organisation decides whether digital therapeutics are reimbursed?
For public coverage in the U.S., reimbursement policy is set by Centers for Medicare & Medicaid Services.
CMS determines:
- which services are reimbursable
- under what conditions
- with what documentation and supervision requirements
Private insurers often follow CMS logic, though not always immediately.
What is actually reimbursed under Medicare today?
As of 2025, Medicare reimburses clinical management of Digital Mental Health Treatment (DMHT) — not the software licence itself.
Payment is tied to:
- clinician time
- therapeutic oversight
- integration into a behavioural health treatment plan
The digital therapeutic must be regulated software, used as part of supervised care.
Is FDA clearance required for reimbursement?
FDA clearance or De Novo classification is necessary but not sufficient.
Regulatory authorisation establishes that the digital therapeutic is a medical device.
Reimbursement additionally requires:
- evidence of clinical benefit
- clinician accountability
- alignment with payer workflows
Many FDA-cleared digital therapeutics have failed to secure sustainable reimbursement because these additional criteria were not met.
When should a digital therapeutics company engage with reimbursement strategy?
Earlier than most companies expect.
Reimbursement considerations should begin:
- during clinical trial design
- when selecting endpoints
- when defining intended use and supervision models
Waiting until after FDA clearance often limits reimbursement options and forces redesigns.
How does a company practically access DMHT reimbursement?
Access is indirect and operational rather than administrative.
Digital therapeutics companies must:
- enable clinicians to prescribe and supervise treatment
- support compliant documentation and time tracking
- integrate with clinical workflows and revenue-cycle processes
Reimbursement succeeds when clinicians can bill correctly and confidently.
Is digital therapeutics reimbursement limited to mental health?
At present, yes under Medicare.
Mental health was chosen first because:
- outcomes are measurable
- supervision models are established
- unmet need is clear
- cost offsets are observable
However, policy proposals indicate that this logic may extend to other conditions through Prescription Digital Therapeutics (PDTx) frameworks.
What is Prescription Digital Therapeutics (PDTx), and who would apply?
PDTx refers to a proposed statutory reimbursement category for regulated digital therapeutics, similar in concept to prescription drugs.
If established, PDTx reimbursement would still be accessed through clinicians and providers, not directly by manufacturers, but would offer clearer national coverage rules.
How long does reimbursement adoption typically take?
Historically, new Medicare reimbursement pathways mature over several years, not months.
Early phases focus on:
- correct use
- documentation quality
- outcome observation
Expansion follows only after CMS is confident that utilisation is appropriate and controllable.
What evidence matters most to payers right now?
Payers prioritise:
- clinically meaningful outcomes
- accountability for treatment decisions
- real-world evidence of use
- signals of economic value (e.g. avoided escalation, improved adherence)
Engagement metrics alone are no longer persuasive.
Who should digital therapeutics teams be talking to?
The most relevant stakeholders are:
- prescribing clinicians
- healthcare systems and clinic operators
- revenue-cycle and compliance teams
- policy and reimbursement specialists
Direct payer outreach is rarely effective without clinical and operational alignment.
What is the most common mistake companies make?
Assuming that regulatory clearance guarantees reimbursement.
Reimbursement is a separate system with its own logic, centred on accountability, budgets, and behaviour — not innovation alone.
Is this relevant outside the U.S.?
Yes.
While this article focuses on U.S. reimbursement, Medicare policy often acts as a reference point for:
- private insurers
- employer plans
- and international health systems evaluating digital therapeutics reimbursement models
Glossary of Terms: Digital Therapeutics Reimbursement
Digital Therapeutics (DTx)
Regulated, evidence-based software interventions designed to prevent, manage, or treat medical conditions. In reimbursement contexts, digital therapeutics are distinguished from wellness or lifestyle apps by their therapeutic intent, clinical evidence, and regulatory status. Only regulated digital therapeutics are eligible for formal healthcare reimbursement.
Digital Therapeutics Reimbursement
The process by which public or private payers compensate healthcare providers for the clinical use and supervision of regulated digital therapeutics. Reimbursement is typically tied to clinical oversight, documentation, and outcomes, rather than software licences or user engagement. In 2025, digital therapeutics reimbursement became operational in the U.S. through Medicare’s DMHT codes.
Medicare
The U.S. federal health insurance programme for people aged 65 and over, certain younger individuals with disabilities, and patients with end-stage renal disease. Medicare reimbursement policy often acts as a global reference point, influencing private insurers, employer health plans, and international health systems.
Centers for Medicare & Medicaid Services (CMS)
The federal agency that administers Medicare and Medicaid. CMS determines which services are reimbursed, under what conditions, and with what documentation requirements. CMS introduced Digital Mental Health Treatment (DMHT) reimbursement codes in the 2025 Medicare Physician Fee Schedule.
Digital Mental Health Treatment (DMHT) Codes
A set of Medicare reimbursement codes introduced in 2025 that allow clinicians to bill for regulated, software-delivered mental health treatment provided under clinical supervision. DMHT codes reimburse clinical management and oversight, not the digital therapeutic product itself. They represent the first formal Medicare reimbursement pathway designed specifically for digital therapeutics.
Reimbursement Code
A billing identifier used by healthcare providers to claim payment from payers. Reimbursement codes define what is paid for, who can bill, under what circumstances, and with what documentation. For digital therapeutics, reimbursement codes determine whether software-delivered treatment is financially viable within routine care.
Physician Fee Schedule (PFS)
An annual Medicare payment framework published by CMS that defines reimbursement rates and billing rules for physician services. The 2025 Physician Fee Schedule formally introduced DMHT codes, marking a structural shift in how digital therapeutics are reimbursed.
Clinical Supervision
A requirement in which a licensed clinician remains accountable for patient care when a digital therapeutic is prescribed. In reimbursement terms, clinical supervision establishes responsibility, auditability, and medical accountability, which are prerequisites for payer coverage.
Regulated Medical Device (Software as a Medical Device – SaMD)
Software that meets the definition of a medical device and is regulated accordingly. For digital therapeutics reimbursement, regulatory classification as SaMD is a necessary but not sufficient condition for payment. Regulation establishes safety and efficacy; reimbursement requires additional alignment with payer rules.
U.S. Food and Drug Administration (FDA)
The U.S. regulatory authority responsible for authorising medical devices, including digital therapeutics classified as Software as a Medical Device. FDA authorisation enables market access but does not guarantee reimbursement.
510(k) Clearance
An FDA regulatory pathway demonstrating that a medical device is substantially equivalent to an existing, legally marketed device. Many digital therapeutics enter the U.S. market through this pathway. Reimbursement decisions are separate and follow different criteria.
De Novo Classification
An FDA pathway for novel medical devices with no direct predicate. Several early digital therapeutics were authorised via De Novo classification. While clinically important, De Novo status alone does not establish reimbursement eligibility.
Prescription Digital Therapeutics (PDTx)
A proposed reimbursement category for regulated digital therapeutics that would function analogously to prescription drugs. PDTx frameworks aim to provide clearer national coverage rules for software-delivered treatment beyond condition-specific codes such as DMHT.
Reimbursement Eligibility
The determination of whether a healthcare service can be paid for under existing payer rules. For digital therapeutics, eligibility depends on regulatory status, therapeutic intent, clinical supervision, and fit with billing frameworks, not on patient engagement or technology novelty.
Clinical Documentation
Records demonstrating how a digital therapeutic is prescribed, supervised, and used within patient care. Documentation is critical for reimbursement compliance, audit readiness, and payer trust.
Outcome Measurement
The collection of clinically meaningful data demonstrating patient benefit. Reimbursement systems prioritise outcomes that are measurable, auditable, and relevant to care pathways, rather than engagement metrics or user satisfaction alone.
Accountability
A core reimbursement principle referring to who is responsible for clinical decisions and patient outcomes. Digital therapeutics reimbursement requires clear accountability, typically anchored to licensed clinicians rather than software vendors.
Health Economics
The analysis of costs, outcomes, and value within healthcare systems. In digital therapeutics reimbursement, health-economic considerations include cost offsets, avoided escalation, and budget impact rather than app-level pricing.
Payer
An organisation responsible for financing healthcare services, including public payers (e.g. Medicare), private insurers, and employer health plans. Payers evaluate digital therapeutics based on evidence, risk, and budgetary impact.
Coverage vs Reimbursement
Coverage refers to whether a payer recognises a service as eligible for payment. Reimbursement refers to how and how much payment occurs. Digital therapeutics may be regulated and covered but still face limited or conditional reimbursement.
Early Adoption Phase
The initial period following introduction of a new reimbursement pathway. For DMHT, early adoption focuses on correct use, documentation quality, and clinical appropriateness, rather than high utilisation or scale.
Auditability
The ability of payers to verify that reimbursed services were delivered appropriately. Auditability is essential for digital therapeutics reimbursement and is enabled through clinical supervision and documentation.
Global Reimbursement Signal
The influence of U.S. Medicare policy on international reimbursement systems. New Medicare reimbursement models for digital therapeutics are often monitored by other countries as reference frameworks.
Engagement Metrics
Measures such as downloads, session frequency, or user time spent. While relevant for product development, engagement metrics alone are not sufficient for reimbursement decisions.
Durable Reimbursement
Sustainable, repeatable payment mechanisms embedded within standard healthcare funding structures. Durable reimbursement contrasts with pilots, grants, or temporary innovation funding.